ID   PRAME_HUMAN             Reviewed;         509 AA.
AC   P78395; B2R6Y7; O43481; Q8IXN8;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   28-JUN-2023, entry version 181.
DE   RecName: Full=Melanoma antigen preferentially expressed in tumors {ECO:0000305};
DE   AltName: Full=Opa-interacting protein 4 {ECO:0000303|PubMed:9466265};
DE            Short=OIP-4 {ECO:0000303|PubMed:9466265};
DE   AltName: Full=Preferentially expressed antigen of melanoma {ECO:0000303|PubMed:9047241};
GN   Name=PRAME {ECO:0000303|PubMed:9047241, ECO:0000312|HGNC:HGNC:9336};
GN   Synonyms=MAPE {ECO:0000312|HGNC:HGNC:9336}, OIP4
GN   {ECO:0000303|PubMed:9466265};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=9047241; DOI=10.1016/s1074-7613(00)80426-4;
RA   Ikeda H., Lethe B.G., Lehmann F., van Baren N., Baurain J.-F., de Smet C.,
RA   Chambost H., Vitale M., Moretta A., Boon T., Coulie P.G.;
RT   "Characterization of an antigen that is recognized on a melanoma showing
RT   partial HLA loss by CTL expressing an NK inhibitory receptor.";
RL   Immunity 6:199-208(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-7.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-7.
RC   TISSUE=Brain, Skin, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 452-509.
RX   PubMed=9466265; DOI=10.1046/j.1365-2958.1998.00670.x;
RA   Williams J.M., Chen G.-C., Zhu L., Rest R.F.;
RT   "Using the yeast two-hybrid system to identify human epithelial cell
RT   proteins that bind gonococcal Opa proteins: intracellular gonococci bind
RT   pyruvate kinase via their Opa proteins and require host pyruvate for
RT   growth.";
RL   Mol. Microbiol. 27:171-186(1998).
RN   [7]
RP   FUNCTION IN RETINOIC ACID SIGNALING, INTERACTION WITH EZH2 AND RARA, AND
RP   MUTAGENESIS OF 470-LEU-LEU-471.
RX   PubMed=16179254; DOI=10.1016/j.cell.2005.07.003;
RA   Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., Bernards R.;
RT   "The human tumor antigen PRAME is a dominant repressor of retinoic acid
RT   receptor signaling.";
RL   Cell 122:835-847(2005).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16620968; DOI=10.1016/j.leukres.2006.02.031;
RA   Proto-Siqueira R., Figueiredo-Pontes L.L., Panepucci R.A., Garcia A.B.,
RA   Rizzatti E.G., Nascimento F.M., Ishikawa H.C.F., Larson R.E., Falcao R.P.,
RA   Simpson A.J., Gout I., Filonenko V., Rego E.M., Zago M.A.;
RT   "PRAME is a membrane and cytoplasmic protein aberrantly expressed in
RT   chronic lymphocytic leukemia and mantle cell lymphoma.";
RL   Leuk. Res. 30:1333-1339(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   FUNCTION, PATHWAY, SUBCELLULAR LOCATION, IDENTIFICATION IN A CRL2 E3
RP   UBIQUITIN-PROTEIN LIGASE COMPLEX, AND MUTAGENESIS OF 26-LEU--ALA-30 AND
RP   48-LEU-PRO-49.
RX   PubMed=21822215; DOI=10.1038/emboj.2011.262;
RA   Costessi A., Mahrour N., Tijchon E., Stunnenberg R., Stoel M.A.,
RA   Jansen P.W., Sela D., Martin-Brown S., Washburn M.P., Florens L.,
RA   Conaway J.W., Conaway R.C., Stunnenberg H.G.;
RT   "The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and
RT   associates with active NFY promoters.";
RL   EMBO J. 30:3786-3798(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9 AND SER-16, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   SUBCELLULAR LOCATION, AND IDENTIFICATION IN A CRL2 E3 UBIQUITIN-PROTEIN
RP   LIGASE COMPLEX.
RX   PubMed=23460923; DOI=10.1371/journal.pone.0058052;
RA   Wadelin F.R., Fulton J., Collins H.M., Tertipis N., Bottley A.,
RA   Spriggs K.A., Falcone F.H., Heery D.M.;
RT   "PRAME is a golgi-targeted protein that associates with the Elongin BC
RT   complex and is upregulated by interferon-gamma and bacterial PAMPs.";
RL   PLoS ONE 8:e58052-e58052(2013).
RN   [13]
RP   FUNCTION, PATHWAY, AND IDENTIFICATION IN A CRL2 E3 UBIQUITIN-PROTEIN LIGASE
RP   COMPLEX.
RX   PubMed=26138980; DOI=10.1126/science.aab0515;
RA   Lin H.C., Ho S.C., Chen Y.Y., Khoo K.H., Hsu P.H., Yen H.C.;
RT   "SELENOPROTEINS. CRL2 aids elimination of truncated selenoproteins produced
RT   by failed UGA/Sec decoding.";
RL   Science 349:91-95(2015).
CC   -!- FUNCTION: Substrate-recognition component of a Cul2-RING (CRL2) E3
CC       ubiquitin-protein ligase complex, which mediates ubiquitination of
CC       target proteins, leading to their degradation (PubMed:21822215,
CC       PubMed:26138980). The CRL2(PRAME) complex mediates ubiquitination and
CC       degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed
CC       UGA/Sec decoding (PubMed:26138980). In the nucleus, the CRL2(PRAME)
CC       complex is recruited to epigenetically and transcriptionally active
CC       promoter regions bound by nuclear transcription factor Y (NFY) and
CC       probably plays a role in chromstin regulation (PubMed:21822215).
CC       Functions as a transcriptional repressor, inhibiting the signaling of
CC       retinoic acid through the retinoic acid receptors RARA, RARB and RARG:
CC       prevents retinoic acid-induced cell proliferation arrest,
CC       differentiation and apoptosis (PubMed:16179254).
CC       {ECO:0000269|PubMed:16179254, ECO:0000269|PubMed:21822215,
CC       ECO:0000269|PubMed:26138980}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:21822215, ECO:0000269|PubMed:26138980}.
CC   -!- SUBUNIT: Component of a CRL2 E3 ubiquitin-protein ligase complex, also
CC       named ECS (Elongin BC-CUL2/5-SOCS-box protein) complex, composed of
CC       CUL2, Elongin BC (ELOB and ELOC), RBX1 and substrate-specific adapter
CC       PRAME (PubMed:21822215, PubMed:23460923, PubMed:26138980). Interacts
CC       with RARA (via the ligand-binding domain); the interaction is direct
CC       and ligand (retinoic acid)-dependent (PubMed:16179254). Interacts with
CC       EZH2; required to repress RAR signaling (PubMed:16179254).
CC       {ECO:0000269|PubMed:16179254, ECO:0000269|PubMed:21822215,
CC       ECO:0000269|PubMed:23460923, ECO:0000269|PubMed:26138980}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21822215,
CC       ECO:0000269|PubMed:23460923, ECO:0000305|PubMed:16620968}. Chromosome
CC       {ECO:0000269|PubMed:21822215}. Cytoplasm {ECO:0000269|PubMed:23460923}.
CC       Golgi apparatus {ECO:0000269|PubMed:23460923}. Cell membrane
CC       {ECO:0000269|PubMed:16620968}. Note=Associates with chromatin;
CC       specifically enriched at transcriptionally active promoters that are
CC       also bound by nuclear transcription factor Y (composed of NFYA, NFYB
CC       and NFYC) and at enhancers (PubMed:21822215). Recruited to the Golgi
CC       apparatus in response to interferon gamma (IFNG) treatment
CC       (PubMed:23460923). {ECO:0000269|PubMed:21822215,
CC       ECO:0000269|PubMed:23460923}.
CC   -!- TISSUE SPECIFICITY: Expressed in testis. Detected in samples of kidney,
CC       brain and skin. {ECO:0000269|PubMed:9047241}.
CC   -!- INDUCTION: Up-regulated in response to interferon gamma (IFNG)
CC       treatment and exposure to bacterial PAMPs (pathogen associated
CC       molecular patterns). {ECO:0000269|PubMed:23460923}.
CC   -!- MISCELLANEOUS: Tumor antigen recognized by cytolytic T lymphocytes.
CC       {ECO:0000269|PubMed:9047241}.
CC   -!- SIMILARITY: Belongs to the PRAME family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U65011; AAC51160.1; -; mRNA.
DR   EMBL; CR456549; CAG30435.1; -; mRNA.
DR   EMBL; AK312769; BAG35634.1; -; mRNA.
DR   EMBL; CH471095; EAW59518.1; -; Genomic_DNA.
DR   EMBL; BC014074; AAH14074.1; -; mRNA.
DR   EMBL; BC022008; AAH22008.1; -; mRNA.
DR   EMBL; BC039731; AAH39731.1; -; mRNA.
DR   EMBL; AF025440; AAC39560.1; -; mRNA.
DR   CCDS; CCDS13801.1; -.
DR   RefSeq; NP_001278644.1; NM_001291715.1.
DR   RefSeq; NP_001278645.1; NM_001291716.1.
DR   RefSeq; NP_001278646.1; NM_001291717.1.
DR   RefSeq; NP_001278648.1; NM_001291719.1.
DR   RefSeq; NP_001305055.1; NM_001318126.1.
DR   RefSeq; NP_001305056.1; NM_001318127.1.
DR   RefSeq; NP_006106.1; NM_006115.4.
DR   RefSeq; NP_996836.1; NM_206953.2.
DR   RefSeq; NP_996837.1; NM_206954.2.
DR   RefSeq; NP_996838.1; NM_206955.2.
DR   RefSeq; NP_996839.1; NM_206956.2.
DR   AlphaFoldDB; P78395; -.
DR   SMR; P78395; -.
DR   BioGRID; 117078; 143.
DR   CORUM; P78395; -.
DR   IntAct; P78395; 32.
DR   MINT; P78395; -.
DR   STRING; 9606.ENSP00000445675; -.
DR   iPTMnet; P78395; -.
DR   PhosphoSitePlus; P78395; -.
DR   BioMuta; PRAME; -.
DR   DMDM; 6685631; -.
DR   EPD; P78395; -.
DR   jPOST; P78395; -.
DR   MassIVE; P78395; -.
DR   MaxQB; P78395; -.
DR   PaxDb; P78395; -.
DR   PeptideAtlas; P78395; -.
DR   ProteomicsDB; 57611; -.
DR   Antibodypedia; 23630; 476 antibodies from 32 providers.
DR   DNASU; 23532; -.
DR   Ensembl; ENST00000398741.5; ENSP00000381726.1; ENSG00000185686.18.
DR   Ensembl; ENST00000398743.6; ENSP00000381728.2; ENSG00000185686.18.
DR   Ensembl; ENST00000402697.5; ENSP00000385198.1; ENSG00000185686.18.
DR   Ensembl; ENST00000405655.8; ENSP00000384343.3; ENSG00000185686.18.
DR   Ensembl; ENST00000539862.2; ENSP00000445097.2; ENSG00000275013.4.
DR   Ensembl; ENST00000543184.5; ENSP00000445675.1; ENSG00000185686.18.
DR   Ensembl; ENST00000617728.4; ENSP00000484066.1; ENSG00000275013.4.
DR   Ensembl; ENST00000626503.2; ENSP00000486485.1; ENSG00000275013.4.
DR   Ensembl; ENST00000628830.2; ENSP00000486330.1; ENSG00000275013.4.
DR   GeneID; 23532; -.
DR   KEGG; hsa:23532; -.
DR   MANE-Select; ENST00000405655.8; ENSP00000384343.3; NM_206956.3; NP_996839.1.
DR   UCSC; uc032qia.2; human.
DR   AGR; HGNC:9336; -.
DR   CTD; 23532; -.
DR   DisGeNET; 23532; -.
DR   GeneCards; PRAME; -.
DR   HGNC; HGNC:9336; PRAME.
DR   HPA; ENSG00000185686; Tissue enriched (testis).
DR   MIM; 606021; gene.
DR   neXtProt; NX_P78395; -.
DR   OpenTargets; ENSG00000185686; -.
DR   PharmGKB; PA33698; -.
DR   VEuPathDB; HostDB:ENSG00000185686; -.
DR   eggNOG; ENOG502QWSJ; Eukaryota.
DR   GeneTree; ENSGT01030000234531; -.
DR   HOGENOM; CLU_039635_2_1_1; -.
DR   InParanoid; P78395; -.
DR   OMA; CPCFMPA; -.
DR   OrthoDB; 5265505at2759; -.
DR   PhylomeDB; P78395; -.
DR   TreeFam; TF332708; -.
DR   PathwayCommons; P78395; -.
DR   SignaLink; P78395; -.
DR   SIGNOR; P78395; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 23532; 26 hits in 1166 CRISPR screens.
DR   ChiTaRS; PRAME; human.
DR   GeneWiki; PRAME; -.
DR   GenomeRNAi; 23532; -.
DR   Pharos; P78395; Tbio.
DR   PRO; PR:P78395; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; P78395; protein.
DR   Bgee; ENSG00000185686; Expressed in right testis and 84 other tissues.
DR   ExpressionAtlas; P78395; baseline and differential.
DR   Genevisible; P78395; HS.
DR   GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR   GO; GO:0031462; C:Cul2-RING ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0042974; F:nuclear retinoic acid receptor binding; IDA:UniProtKB.
DR   GO; GO:1990756; F:ubiquitin ligase-substrate adaptor activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR026271; PRAME_family.
DR   PANTHER; PTHR14224:SF24; MELANOMA ANTIGEN PREFERENTIALLY EXPRESSED IN TUMORS; 1.
DR   PANTHER; PTHR14224; SIMILAR TO PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA-LIKE 3; 1.
DR   PIRSF; PIRSF038286; PRAME; 1.
DR   SUPFAM; SSF52047; RNI-like; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; Cell membrane; Chromosome; Cytoplasm; Differentiation;
KW   Golgi apparatus; Growth regulation; Leucine-rich repeat; Membrane; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation pathway.
FT   CHAIN           1..509
FT                   /note="Melanoma antigen preferentially expressed in tumors"
FT                   /id="PRO_0000156973"
FT   REPEAT          116..145
FT                   /note="LRR 1; degenerate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REPEAT          207..231
FT                   /note="LRR 2; degenerate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REPEAT          232..258
FT                   /note="LRR 3; degenerate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REPEAT          259..294
FT                   /note="LRR 4; degenerate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REPEAT          295..320
FT                   /note="LRR 5"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REPEAT          321..352
FT                   /note="LRR 6"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REPEAT          353..371
FT                   /note="LRR 7"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REPEAT          377..404
FT                   /note="LRR 8"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REPEAT          405..429
FT                   /note="LRR 9"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UWY1"
FT   REGION          416..509
FT                   /note="Mediates interaction with RARA"
FT                   /evidence="ECO:0000269|PubMed:16179254"
FT   MOD_RES         9
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         16
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         7
FT                   /note="W -> R (in dbSNP:rs1129172)"
FT                   /evidence="ECO:0000269|PubMed:15461802,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_021258"
FT   VARIANT         218
FT                   /note="M -> V (in dbSNP:rs41277507)"
FT                   /id="VAR_062137"
FT   MUTAGEN         26..30
FT                   /note="LVELA->PVELF: Impaired formation of the CRL2(PRAME)
FT                   complex."
FT                   /evidence="ECO:0000269|PubMed:21822215"
FT   MUTAGEN         48..49
FT                   /note="LP->AA: Impaired formation of the CRL2(PRAME)
FT                   complex."
FT                   /evidence="ECO:0000269|PubMed:21822215"
FT   MUTAGEN         470..471
FT                   /note="LL->VV: Loss of interaction with RARA and defective
FT                   in repressing RARA signaling."
FT                   /evidence="ECO:0000269|PubMed:16179254"
FT   CONFLICT        452
FT                   /note="H -> D (in Ref. 6; AAC39560)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   509 AA;  57890 MW;  B5FFF3E7F7E82606 CRC64;
     MERRRLWGSI QSRYISMSVW TSPRRLVELA GQSLLKDEAL AIAALELLPR ELFPPLFMAA
     FDGRHSQTLK AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ
     VLDLRKNSHQ DFWTVWSGNR ASLYSFPEPE AAQPMTKKRK VDGLSTEAEQ PFIPVEVLVD
     LFLKEGACDE LFSYLIEKVK RKKNVLRLCC KKLKIFAMPM QDIKMILKMV QLDSIEDLEV
     TCTWKLPTLA KFSPYLGQMI NLRRLLLSHI HASSYISPEK EEQYIAQFTS QFLSLQCLQA
     LYVDSLFFLR GRLDQLLRHV MNPLETLSIT NCRLSEGDVM HLSQSPSVSQ LSVLSLSGVM
     LTDVSPEPLQ ALLERASATL QDLVFDECGI TDDQLLALLP SLSHCSQLTT LSFYGNSISI
     SALQSLLQHL IGLSNLTHVL YPVPLESYED IHGTLHLERL AYLHARLREL LCELGRPSMV
     WLSANPCPHC GDRTFYDPEP ILCPCFMPN
//
